RBD5044 – a novel anti-APOC3 GalNAc-siRNA drug resulted in sustained and profound reduction of triglycerides in mice and Rhesus monkeys

Targeting liver angiotensinogen using a GalNAc-siRNA improves cardiac remodeling in spontaneously hypertensive rats

The Effect of HSD17B13-targeting siRNA - R0737072 on Improvement of Liver Fibrosis and Steatosis in a NASH Mouse Model